DUBLIN, Dec. 11, 2014 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/hcq6dq/global_fabry) has announced the addition of the "Global Fabry Disease Market 2015-2019" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

Fabry disease is an inheritable lysosomal storage disease characterized by the excessive accumulation of globotriaosylceramide (GL-3) in lysosomes. It results from a deficiency of a-Gal and can result in symptoms such as fatigue, angiokeratoma, tinnitus, kidney failure, heart disorders, and nervous system problems. Fabry disease results from mutations in the galactosidase (GLA) gene, resulting in decreased activity or complete absence of a-Gal.

Fabry disease resulting from the decreased activity of the enzyme is called later-onset Fabry disease. This form of the disease can effect both males and females. The symptoms of this disease typically appear during adulthood and usually focus on a single organ. Fabry disease resulting from the complete absence of a-Gal results in a more severe form called classic Fabry disease. The classic form of the disease usually affects males.

The disease symptoms usually starts in adolescence and include clouded eye lenses, skin lesions, pain, and reduced sweating. If untreated, the disease can lead to cardiac dysfunction, renal failure or stroke, often resulting in death during fourth or fifth decade of life.

The analysts forecast the Global Fabry Disease market to grow at a CAGR of 18.08 percent over the period 2014-2019.

This report covers the present scenario and the growth prospects of the Global Fabry Disease market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various innovator drugs available in the market for the treatment of fabry disease.

The report, the Global Fabry Disease Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Fabry Disease market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

One key trend in the market is an increase in regulatory assistance in emerging nations. Regulatory bodies are steadily working toward developing guidelines and providing assistance to drug manufacturers to promote research in this area.

According to the report, special provisions for orphan drugs are one of the major drivers of this market. Special incentives in the form of funding, guidance, and market exclusivity offer an attractive opportunity to vendors to conduct research in this area.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Disease Overview

06. Introduction

07. Market Landscape

08. Market Segmentation by Cell Line Used for Manufacturing the Drug

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

18. Pipeline Analysis

19. Fabry Registry

20. Key Vendor Analysis

21. Other Reports in this Series

Companies Mentioned:

• Genzyme
• Shire
• Amicus Therapeutics
• Green Cross Corporation
• ISU Abxis
• JCR Pharmaceuticals
• Protalix Biotherapeutics

For more information visit http://www.researchandmarkets.com/research/hcq6dq/global_fabry

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets